MARKET

PMN

PMN

Promis Neuroscie
NASDAQ
8.27
+0.14
+1.72%
After Hours: 8.10 -0.17 -2.06% 14:27 12/24 EST
OPEN
8.13
PREV CLOSE
8.13
HIGH
8.73
LOW
8.09
VOLUME
17.31K
TURNOVER
--
52 WEEK HIGH
39.75
52 WEEK LOW
6.27
MARKET CAP
17.80M
P/E (TTM)
-0.4442
1D
5D
1M
3M
1Y
5Y
1D
ProMIS Neurosciences (PMN) Gets a Buy from Maxim Group
TipRanks · 1d ago
Weekly Report: what happened at PMN last week (1215-1219)?
Weekly Report · 3d ago
After-Hours Biotech Rally: Inspira, MediciNova, DiaMedica Therapeutics Among Gainers
NASDAQ · 6d ago
ProMIS Neurosciences exceeds target enrollment in PRECISE-AD
TipRanks · 6d ago
ProMIS Neurosciences Completes Enrollment Of 144 Patients In PRECISE-AD Phase 1b Clinical Trial, Evaluating PMN310, Therapeutic Antibody Candidate For Treatment Of AD
Benzinga · 6d ago
ProMIS Neurosciences Completes Enrollment for Phase 1b Trial of PMN310 in Alzheimer’s Disease
Reuters · 6d ago
PROMIS NEUROSCIENCES EXCEEDS TARGET ENROLLMENT IN PRECISE-AD PHASE 1B CLINICAL TRIAL OF PMN310 IN ALZHEIMER’S DISEASE
Reuters · 6d ago
PROMIS NEUROSCIENCES INC - INTERIM ANALYSIS EXPECTED IN Q2 2026, FINAL RESULTS IN Q4 2026
Reuters · 6d ago
More
About PMN
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

Webull offers Promis Neurosciences Inc stock information, including NASDAQ: PMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PMN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PMN stock methods without spending real money on the virtual paper trading platform.